Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Director | September 12, 2016 | September 14, 2016 |
| ARRAY BIOPHARMA INCARRY · Entity 155788 | VP, General Counsel | April 01, 2017 | April 06, 2017 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | General Counsel | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date September 12, 2016 · Filed September 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.77 · Expires 2026-09-12 | Direct | 12,300 |
Reported balance
After 2016-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-12 · Grant · Acquired 12,300 · Balance 12,300 F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F2: The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
ARRAY BIOPHARMA INC
Report date April 01, 2017 · Filed April 06, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,102 |
Reported balance
After 2017-04-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-04-01 · Tax withholding · Disposed 6,370 · Balance 40,102 F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment to form 4 is being filed to correct number of shares withheld to satisfy the reporting person's tax withholding obligations in connection with the vesting of Restricted Stock Units, and to correct the ending balance previously reported on a form 4 by the reporting person. No other information in such form 4 is being amended.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 10 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F9 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 32,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2036-08-12 F8 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 6,718 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,157 Underlying: Common Stock · 6,718 shares Expires 2035-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · derivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,563 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,419 | $43.80 | $105,948.57 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,697 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 99 | $44.50 | $4,405.69 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,116 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 59 | $44.41 | $2,620.44 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,215 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,439 | $43.81 | $106,847.96 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,274 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 6,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001191702-26-000001 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:40 UTC Amendment | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001191702-26-000002 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 161,250 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,250 Underlying: Common Stock · 161,250 shares Expires 2035-08-12 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 26,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,875 Underlying: Common Stock · 26,875 shares Expires 2035-08-12 F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005799 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,344 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,098 | $13.39 | $28,097.26 |
DisclosureSEC source: 0001562180-25-005799 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,214 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005799 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,930 | $16.45 | $31,756.61 |
DisclosureSEC source: 0001562180-25-003659 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,531 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,209 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003659 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,209 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003659 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,922 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · derivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,636 Underlying: Common Stock · 20,922 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 20,922 | $27.63 | $578,064.40 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,252 Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 20,922 | $0.71 | $14,854.62 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · derivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Common Stock · 50,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 50,000 | $28.37 | $1,418,510.00 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,252 Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 50,000 | $0.71 | $35,500.00 |
DisclosureSEC source: 0001562180-24-006946 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 23,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006260 · primarydocument.xml · derivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006260 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:31 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,956 | $18.91 | $36,987.96 |
DisclosureSEC source: 0001562180-24-003830 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,252 F1 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:31 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003830 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:31 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003830 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,029 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · derivative · entry 9 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,162 Underlying: Common Stock · 8,029 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,029 | $20.01 | $160,657.08 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 6 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 8,029 | $1.93 | $15,495.97 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 5 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,813 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · derivative · entry 8 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,191 Underlying: Common Stock · 3,813 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,813 | $20.01 | $76,284.78 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 3,813 | $1.93 | $7,359.09 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,993 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · derivative · entry 7 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,004 Underlying: Common Stock · 17,993 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 17,993 | $20.00 | $359,863.60 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,993 | $1.93 | $34,726.49 |
DisclosureSEC source: 0001562180-24-001227 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 30, 2023. Read SEC document |
| December 27, 2023 Filed Dec 28, 2023 21:39 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,497 | $10.50 | $89,218.50 |
DisclosureSEC source: 0001562180-23-008572 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 30, 2023. F2 · shares: Includes 1,932 shares purchased on May 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006456 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,897 | $8.90 | $16,892.60 |
DisclosureSEC source: 0001562180-23-003922 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,565 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003922 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003922 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 254 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,730 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-007050 · primarydocument.xml · derivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,997 Underlying: Common Stock · 4,730 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,730 | $9.76 | $46,154.87 |
DisclosureSEC source: 0001562180-22-007050 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.47 to $10.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,730 | $1.93 | $9,128.90 |
DisclosureSEC source: 0001562180-22-007050 · primarydocument.xml · nonDerivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,730 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-22-006557 · primarydocument.xml · derivative · entry 4 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,727 Underlying: Common Stock · 4,730 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly beginning on January 16, 2021, subject to Reporting Person continuing as a service provider through each vest date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,351 | $10.99 | $25,842.19 |
DisclosureSEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 3 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $10.93 to $11.08, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 20:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,379 | $10.83 | $25,755.53 |
DisclosureSEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 2 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,351 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.